Aclarion adds NYU Langone Health as clinical site for CLARITY trial of Nociscan in chronic low back pain

• Aclarion added NYU Langone Health as a new enrolling site for its CLARITY randomized trial evaluating Nociscan in spine surgery.
• No trial results were presented; the study is ongoing, with outcomes to be assessed at 12 months.
• The trial aims to show Nociscan improves surgical outcomes for chronic low back pain by better identifying pain-generating discs.
• CLARITY targets 300 patients across multiple centers, expanding Aclarion’s clinical footprint for its MR spectroscopy and AI-based platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290700PRIMZONEFULLFEED9834096) on September 29, 2026, and is solely responsible for the information contained therein.